An international collaboration of researchers, sponsored by GSK and working on behalf of the ANCHOR-1 and ANCHOR-2 trial investigators, conducted two Phase III clinical trials to evaluate depemokimab, ...
NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), today announced positive topline data from VESPER-1 and positive data from a planned interim analysis for tolerability of ...
GSK plc GSK announced that the FDA has approved Exdensur (depemokimab-ulaa), an ultra-long-acting IL-5–targeting biologic, as an add-on maintenance treatment of severe asthma with an eosinophilic ...
SAN DIEGO -- Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel phase III trials showed. Twice-yearly injections cut total nasal polyps score by ...
The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced. The ...
GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently ...
HONG KONG, April 1, 2026 /PRNewswire/ -- The release of Innogen's inaugural annual report following its Hong Kong listing serves not merely as a financial disclosure, but as a strategic ...
Please provide your email address to receive an email when new articles are posted on . When assessing annualized exacerbation rates in patients who switched to ...
Different materials, different outcomes: Time-to-recurrence was longest for long-acting resorbable meshes (166.4 months), followed by synthetic meshes (132.1 months), and shortest for biologic meshes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results